Kairos Pharma Signs Term Sheet to Acquire Two Clinical Oncology Assets
Kairos Pharma signed a term sheet to acquire two clinical oncology assets from Celyn Therapeutics, subject to definitive agreements and approvals. The assets will expand Kairos’s clinical pipeline and target key solid tumor indications.
1. Term Sheet Signed for Oncology Asset Acquisition
Kairos Pharma announced the signing of a term sheet with Celyn Therapeutics to acquire two clinical-stage oncology assets. The agreement outlines the framework for the strategic purchase, with final terms and regulatory clearances to be negotiated in definitive agreements.
2. Pipeline Expansion with Clinical Oncology Assets
The two assets will be integrated into Kairos’s development pipeline, enhancing its focus on solid tumor therapies. This acquisition aims to accelerate Kairos’s progression toward later-stage clinical trials and broaden its oncology portfolio.